Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
12:40pm, Wednesday, 09'th Jul 2025
Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead's twice-yearly injecta
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 09'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
10:30am, Wednesday, 09'th Jul 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries
08:16am, Wednesday, 09'th Jul 2025
Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund)
Final Trades: Synovus, Nextera Energy, Gilead and the IYF
01:23pm, Tuesday, 08'th Jul 2025
The Investment Committee give you their top stocks to watch for the second half.
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
10:56am, Tuesday, 08'th Jul 2025
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
10:41am, Tuesday, 08'th Jul 2025
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
10:40am, Tuesday, 08'th Jul 2025
Here is how Gilead Sciences (GILD) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
It is time for a move higher in biotech, says Mizuho's Jared Holz
06:29pm, Monday, 07'th Jul 2025
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
04:07pm, Monday, 07'th Jul 2025
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
10:00am, Sunday, 06'th Jul 2025
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investor
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
08:54am, Saturday, 05'th Jul 2025
nvestors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance o
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
10:00am, Wednesday, 02'nd Jul 2025
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised
Gilead Sciences: A Mixed Bag of Opportunities and Risks
07:00pm, Tuesday, 01'st Jul 2025
Explore the exciting world of Gilead Sciences (GILD 0.79%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and p
